Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
36, No. 1, 2012
Issue release date: February 2013
Section title: Original Paper
Kidney Blood Press Res 2012;36:344-354

Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Chronic Cardiorenal Failure is Correlated with Endogenous Erythropoietin Levels and Decreases in Response to Low-Dose Erythropoietin Treatment

Emans M.E.a · Braam B.b · Diepenbroek A.c · van der Putten K.d · Cramer M.J.a · Wielders J.P.M.e · Swinkels D.W.f · Doevendans P.A.a,g · Gaillard C.A.c,h
aDept. of Cardiology, University Medical Centre Utrecht, the Netherlands, bDivision of Nephrology and Immunology, Dept. Medicine, University of Alberta, Edmonton, Canada, cDept. of Internal Medicine, Meander Medical Centre Amersfoort, the Netherlands, dDept. of Nephrology, Leiden University Medical Center, the Netherlands, eDept. of Clinical Chemistry, Meander Medical Centre Amersfoort, the Netherlands, fLaboratory of Genetic, Endocrine and Metabolic Diseases, Dept. of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands, gInteruniversitary Cardiological Institute (ICIN), the Netherlands, hDepartment of Nephrology, VU University Medical Centre, Amsterdam, the Netherlands
email Corresponding Author

Carlo A.J.M. Gaillard, MD, PhD

Department of Nephrology, VU University Medical Center, PO Box7057

1007 MB Amsterdam (The Netherlands)

Tel. +31 204444312, Fax +31 204444960, E-Mail c.gaillard@vumc.nl

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Neutrophil-gelatinase associated lipocalin (NGAL), a tubular injury marker, is associated with iron metabolism in hemodialysis patients. We investigated whether serum NGAL levels reflect iron metabolism in combined chronic heart failure and chronic kidney disease (CHF/CKD) and whether treatment with low-dose erythropoietin stimulating agent (ESA) modulates NGAL levels. Methods: In the EPOCARES trial (ClinTrialsNCT00356733) serum NGAL, hepcidin-25, transferrin saturation (TSAT), reticulocyte hemoglobin content (Ret-He) and endogenous erythropoietin (EPO) levels were measured. Results: Baseline serum NGAL levels correlated with cystatin C (r=0.767, p<0.001) and baseline EPO levels (r=-0.395, p=0.003). There was no correlation with baseline TSAT, Ret-He, and hepcidin-25 levels. After two weeks, NGAL levels decreased in the ESA-group (p=0.02), while there was no change in the no-ESA group (p=0.62). The magnitude in NGAL decrease in the ESA-group correlated with baseline EPO levels (r=0.431, p=0.01). Conclusions: In contrast to in HD patients, in combined CKD/ CHF, serum NGAL levels did not correlate with iron metabolism, hence NGAL might reflect tubular damage in these patients. NGAL levels inversely correlated with baseline EPO levels and decreased in response to short-term ESA treatment, which might reflect an effect of ESA on tubular damage. These findings need to be confirmed and alternative explanations should be evaluated.

© 2012 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: November 20, 2012
Published online: December 12, 2012
Issue release date: February 2013

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: http://www.karger.com/KBR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.